ACM
PTGX icon

Aquilo Capital Management’s Protagonist Therapeutics PTGX Stock Holding History

Aquilo Capital Management’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-81,692
Closed -$3.95M – 10
2025
Q1 		$3.95M Buy
81,692
+5,100
+7% +$214K 7.08% 4
2024
Q4 		$2.96M Buy
+76,592
New +$3.34M 4.46% 7

Other funds holding PTGX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Aquilo Capital Management's PTGX Position: Q2 2025 in Review

Aquilo Capital Management sold out of Protagonist Therapeutics (PTGX) in Q2 2025, closing a stake of 81,692 shares — an estimated $3.95M sold.

Aquilo Capital Management first reported a position in PTGX in Q4 2024 and held it in 2 quarters. The position peaked at $3.95M in Q1 2025. 273 funds tracked by Wall St. Rank hold PTGX as of Q2 2025.

  • Aquilo Capital Management reported no remaining Protagonist Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Aquilo Capital Management sold 81,692 Protagonist Therapeutics shares in Q2 2025, an estimated $3.95M.
  • Aquilo Capital Management first reported a position in Protagonist Therapeutics in Q4 2024 and held it in 2 quarters.
  • Aquilo Capital Management's Protagonist Therapeutics position peaked at $3.95M in Q1 2025.
  • 273 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2025.

Based on Aquilo Capital Management's 13F filing for Q2 2025.